

Danxin Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5810001/publications.pdf>

Version: 2024-02-01

86
papers

5,519
citations

109321

35
h-index

79698

73
g-index

87
all docs

87
docs citations

87
times ranked

7217
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 16-23.	1.5	9
2	Transcriptional Regulation of Carboxylesterase 1 in Human Liver: Role of the Nuclear Receptor Subfamily 1 Group H Member 3 and Its Splice Isoforms. <i>Drug Metabolism and Disposition</i> , 2022, 50, 43-48.	3.3	0
3	ESR1 CHIP-Seq Identifies Distinct Ligand-Free ESR1 Genomic Binding Sites in Human Hepatocytes and Liver Tissue. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1461.	4.1	8
4	Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients. <i>Pharmacogenomics Journal</i> , 2021, 21, 376-389.	2.0	5
5	Co-expression of drug metabolizing cytochrome P450 enzymes and estrogen receptor alpha (ESR1) in human liver: racial differences and the regulatory role of ESR1. <i>Drug Metabolism and Personalized Therapy</i> , 2021, 36, 205-214.	0.6	11
6	Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1558-1569.	4.7	8
7	Cytochrome P450 3A4 (CYP3A4) protein quantification using capillary western blot technology and total protein normalization. <i>Journal of Pharmacological and Toxicological Methods</i> , 2021, 112, 107117.	0.7	7
8	Cis-acting regulatory elements regulating CYP3A4 transcription in human liver. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 107-116.	1.5	9
9	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across <i>CYP2D6</i> Genotype-Derived Activity Scores. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 678-685.	2.5	13
10	SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 347-356.	2.8	14
11	Abstract 15986: Plasma Microrna Profiling Reveals Potential Biomarkers of Thiazide Response. <i>Circulation</i> , 2020, 142, .	1.6	0
12	Ligand-Free Estrogen Receptor <i>ERα</i> (ESR1) as Master Regulator for the Expression of CYP3A4 and Other Cytochrome P450 Enzymes in the Human Liver. <i>Molecular Pharmacology</i> , 2019, 96, 430-440.	2.3	26
13	XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2019, 58, 2327-2339.	2.7	7
14	Association of Regulatory Genetic Variants for Protein Kinase <i>PKCε</i> with Mortality and Drug Efficacy in Patients with Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 693-700.	2.6	0
15	CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele). <i>Pharmacogenetics and Genomics</i> , 2019, 29, 39-47.	1.5	21
16	Response to the Comments on "Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Proteomics Method". <i>Journal of Proteome Research</i> , 2019, 18, 1458-1459.	3.7	0
17	A comparison of genetic sampling methodologies for candidate-gene analyses. <i>Journal of Translational Science</i> , 2019, 5, .	0.2	0
18	Estimation of Sobol's sensitivity indices under generalized linear models. <i>Communications in Statistics - Theory and Methods</i> , 2018, 47, 5163-5195.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Dissecting CYP3A interactome to understand the causes of CYP3A variability. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, S83-S84.	2.2	0
20	Interactions Between Regulatory Variants in <i>CYP7A1</i> (Cholesterol 7 α -Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002082.	3.6	18
21	Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method. <i>Journal of Proteome Research</i> , 2018, 17, 3606-3612.	3.7	20
22	Regulatory Variants Modulate Protein Kinase C δ (PRKCA) Gene Expression in Human Heart. <i>Pharmaceutical Research</i> , 2017, 34, 1648-1657.	3.5	10
23	The <i>CHRNA5/CHRNA3/CHRNA4</i> Nicotinic Receptor Regulome: Genomic Architecture, Regulatory Variants, and Clinical Associations. <i>Human Mutation</i> , 2017, 38, 112-119.	2.5	34
24	Intronic SNP in ESR1 encoding human estrogen receptor alpha is associated with brain ESR1 mRNA isoform expression and behavioral traits. <i>PLoS ONE</i> , 2017, 12, e0179020.	2.5	14
25	CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 40-43.	1.5	76
26	Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 197-207.	1.5	18
27	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for <i>CYP3A5</i> Genotype and Tacrolimus Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 19-24.	4.7	491
28	Conditional entropy in variation-adjusted windows detects selection signatures associated with expression quantitative trait loci (eQTLs). <i>BMC Genomics</i> , 2015, 16, S8.	2.8	3
29	Regulation of cholesteryl ester transfer protein expression by upstream polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 394-401.	1.5	10
30	Allele-Selective Transcriptome Recruitment to Polysomes Primed for Translation: Protein-Coding and Noncoding RNAs, and RNA Isoforms. <i>PLoS ONE</i> , 2015, 10, e0136798.	2.5	15
31	Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in <i>Psychopharmacology</i> 232, 305-314, 2014. <i>Psychopharmacology</i> , 2015, 232, 1493-1494.	3.1	0
32	Analyzing allele specific RNA expression using mixture models. <i>BMC Genomics</i> , 2015, 16, 566.	2.8	8
33	Functional characterization of CYP2D6 enhancer polymorphisms. <i>Human Molecular Genetics</i> , 2015, 24, 1556-1562.	2.9	58
34	Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. <i>Human Molecular Genetics</i> , 2014, 23, 1957-1963.	2.9	82
35	Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. <i>Human Molecular Genetics</i> , 2014, 23, 268-278.	2.9	101
36	A Prospective, Double-Blinded, Observational Clinical Cohort Study of the Association Between Tacrolimus Exposure and CYP3A4, CYP3A5 Genotypes in Adult Hematopoietic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S380.	2.0	1

#	ARTICLE	IF	CITATIONS
37	<i>CYP3A4/5</i> combined genotype analysis for predicting statin dose requirement for optimal lipid control. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 59-63.	0.3	20
38	Regulatory polymorphisms in <i>CYP2C19</i> affecting hepatic expression. <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 23-30.	0.3	28
39	<i>CYP2C9</i> promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in <i>CYP2C9</i> -mediated effects. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 228-231.	1.5	19
40	<i>CYP2D6</i> expression is regulated by polymorphisms that affect splicing and transcription: new biomarkers for <i>CYP2D6</i> activity. <i>FASEB Journal</i> , 2013, 27, 663.6.	0.5	0
41	Polymorphisms of the <i>SAMHD1</i> Gene Are Not Associated with the Infection and Natural Control of HIV Type 1 in Europeans and African-Americans. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1565-1573.	1.1	17
42	Polymorphism in glutamate cysteine ligase catalytic subunit (<i>GCLC</i>) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients. <i>BMC Medical Genomics</i> , 2012, 5, 32.	1.5	30
43	Cholesteryl Ester Transfer Protein (<i>CETP</i>) Polymorphisms Affect mRNA Splicing, HDL Levels, and Sex-Dependent Cardiovascular Risk. <i>PLoS ONE</i> , 2012, 7, e31930.	2.5	59
44	The Making of a <i>CYP3A</i> Biomarker Panel for Guiding Drug Therapy. <i>Journal of Personalized Medicine</i> , 2012, 2, 175-191.	2.5	22
45	<i>CYP2C9</i> Promoter Variable Number Tandem Repeat Polymorphism Regulates mRNA Expression in Human Livers. <i>Drug Metabolism and Disposition</i> , 2012, 40, 884-891.	3.3	11
46	Intronic Polymorphisms Affecting Alternative Splicing of Human Dopamine D2 Receptor Are Associated with Cocaine Abuse. <i>Neuropsychopharmacology</i> , 2011, 36, 753-762.	5.4	128
47	Intronic polymorphism in <i>CYP3A4</i> affects hepatic expression and response to statin drugs. <i>Pharmacogenomics Journal</i> , 2011, 11, 274-286.	2.0	412
48	Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 652-664.	1.5	44
49	Nicotinic $\alpha 5$ receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms. <i>European Journal of Human Genetics</i> , 2011, 19, 76-83.	2.8	58
50	Common alleles in human N-acetyltransferase 1 (<i>NAT1</i> *10 and *11) increase enzyme activity via distinct mechanisms and associate with sulfamethoxazole induced hypersensitivity. <i>FASEB Journal</i> , 2011, 25, .	0.5	0
51	Allele-specific tumor spectrum in <i>Pten</i> knockin mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5142-5147.	7.1	59
52	Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. <i>Brain</i> , 2009, 132, 417-425.	7.6	123
53	Promoter Polymorphisms in <i>ACE</i> (Angiotensin Converting Enzyme) Associated With Clinical Outcomes in Hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 36-44.	4.7	33
54	<i>CACNA1C</i> Gene Polymorphisms, Cardiovascular Disease Outcomes, and Treatment Response. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 362-370.	5.1	58

#	ARTICLE	IF	CITATIONS
55	Genotyping panel for assessing response to cancer chemotherapy. <i>BMC Medical Genomics</i> , 2008, 1, 24.	1.5	24
56	Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 781-791.	1.5	90
57	Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. <i>Blood</i> , 2008, 112, 1013-1021.	1.4	187
58	Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20552-20557.	7.1	378
59	Different Effects of Opioid Antagonists on μ , κ , and δ -Opioid Receptors with and without Agonist Pretreatment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 544-552.	2.5	80
60	KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the International Verapamil SR/Trandolapril Study (INVEST). <i>Pharmacogenetics and Genomics</i> , 2007, 17, 719-729.	1.5	65
61	Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 735-745.	1.5	83
62	Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1). <i>AAPS Journal</i> , 2006, 8, E515-E520.	4.4	92
63	Calmodulin Binding to Peptides Derived from the i3 Loop of Muscarinic Receptors. <i>Pharmaceutical Research</i> , 2006, 23, 647-653.	3.5	21
64	Calmodulin Binding to Peptides Derived from the i3 Loop of Muscarinic Receptors. <i>Pharmaceutical Research</i> , 2006, 23, 647.	3.5	2
65	Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 693-704.	1.5	419
66	Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics. , 2005, 106, 19-38.		83
67	In Vivo Characterization of μ -Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1150-1162.	2.5	80
68	Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G. <i>Journal of Biological Chemistry</i> , 2005, 280, 32618-32624.	3.4	490
69	Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer. <i>Molecular Pharmacology</i> , 2005, 67, 2173-2184.	2.3	142
70	Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. <i>Life Sciences</i> , 2005, 76, 1427-1437.	4.3	88
71	Calmodulin interaction with peptides from G-protein coupled receptors measured with S-Tag labeling. <i>Biochemical and Biophysical Research Communications</i> , 2005, 333, 390-395.	2.1	8
72	Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 693-704.	1.5	166

#	ARTICLE	IF	CITATIONS
73	Basal Signaling Activity of μ Opioid Receptor in Mouse Brain: Role in Narcotic Dependence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 512-520.	2.5	77
74	Serum Response Factor Activation by Muscarinic Receptors via RhoA. <i>Journal of Biological Chemistry</i> , 2002, 277, 40789-40798.	3.4	18
75	Differential Effects of μ -Opioid Receptor Ligands on Ca^{2+} Signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 1002-1012.	2.5	32
76	Nuclear Ca^{2+} /Calmodulin Translocation Activated by μ -Opioid (OP_3) Receptor. <i>Journal of Neurochemistry</i> , 2002, 74, 1418-1425.	3.9	40
77	Calmodulin Regulation of Basal and Agonist-Stimulated G Protein Coupling by the μ -Opioid Receptor (OP_3) in Morphine-Pretreated Cell. <i>Journal of Neurochemistry</i> , 2002, 75, 763-771.	3.9	38
78	Inverse agonists and neutral antagonists at μ -opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. <i>Journal of Neurochemistry</i> , 2001, 77, 1590-1600.	3.9	118
79	Genetic variations in human G protein-coupled receptors: Implications for drug therapy. <i>AAPS PharmSci</i> , 2001, 3, 54-80.	1.3	42
80	μ -Opioid Receptor-mediated ERK Activation Involves Calmodulin-dependent Epidermal Growth Factor Receptor Transactivation. <i>Journal of Biological Chemistry</i> , 2001, 276, 33847-33853.	3.4	113
81	Single Nucleotide Polymorphisms in the Human μ Opioid Receptor Gene Alter Basal G Protein Coupling and Calmodulin Binding. <i>Journal of Biological Chemistry</i> , 2001, 276, 34624-34630.	3.4	67
82	G-protein coupling of μ -opioid receptors (OP_3): elevated basal signalling activity. <i>Biochemical Journal</i> , 2000, 348, 531.	3.7	27
83	G-protein coupling of μ -opioid receptors (OP_3): elevated basal signalling activity. <i>Biochemical Journal</i> , 2000, 348, 531-537.	3.7	69
84	Basal signaling activity of human dopamine D2L receptor demonstrated with an ecdysone-inducible mammalian expression system. <i>Journal of Neuroscience Methods</i> , 2000, 94, 217-225.	2.5	13
85	Calmodulin Binding to G Protein-coupling Domain of Opioid Receptors. <i>Journal of Biological Chemistry</i> , 1999, 274, 22081-22088.	3.4	114
86	3-Isobutyl-1-methylxanthine inhibits basal μ -opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice. <i>European Journal of Pharmacology</i> , 1999, 371, 1-9.	3.5	22